Affimed NV at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hey, everybody. It's Alethia Young here at Cantor. I cover large-cap, small and mid-cap biotech. Very happy to have Affimed, and I have Adi Hoess who is the CEO of the Company and will be doing a formal presentation for the whole 30 minutes. So with that, I will turn it over to Adi.
Thank you, Alethia, and welcome, everybody. And yes, thanks for listening to my presentation about what Affimed does. As you can see by my title, we are indeed working on activating innate immunity, in particular, to treat cancer patients. We are doing this by the use of innate cell engagers. Now these are bispecific antibodies that on the one side, have the opportunity to attach to innate cells, which can be natural killer cells on macrophages and on the other side, attached to cancer cells. This approach indeed has the opportunity to elicit a full immune response as activation of the innate immune system is also a promising approach to activate the adaptive immune system.
Now why are we doing it? It
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
